JPMorgan Chase & Co. Cuts Ascendis Pharma A/S (NASDAQ:ASND) Price Target to $165.00

Ascendis Pharma A/S (NASDAQ:ASND) had its price target decreased by JPMorgan Chase & Co. from $174.00 to $165.00 in a research report report published on Wednesday morning, Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the biotechnology company’s stock.

Several other brokerages have also recently commented on ASND. Bank of America raised their target price on Ascendis Pharma A/S from $165.00 to $175.00 and gave the stock a buy rating in a research report on Wednesday. Wells Fargo & Company decreased their price objective on Ascendis Pharma A/S from $277.00 to $264.00 and set an overweight rating for the company in a research report on Wednesday. Cantor Fitzgerald dropped their target price on Ascendis Pharma A/S from $173.00 to $170.00 and set an overweight rating on the stock in a report on Wednesday. StockNews.com cut shares of Ascendis Pharma A/S from a hold rating to a sell rating in a report on Tuesday, August 13th. Finally, Stifel Nicolaus began coverage on shares of Ascendis Pharma A/S in a research note on Friday, May 31st. They issued a buy rating and a $200.00 price objective on the stock. Two investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of Moderate Buy and an average price target of $187.08.

Ascendis Pharma A/S Stock Performance

Shares of NASDAQ:ASND opened at $119.15 on Wednesday. The firm has a 50 day simple moving average of $134.38 and a 200 day simple moving average of $138.07. Ascendis Pharma A/S has a 52 week low of $85.29 and a 52 week high of $161.00. The company has a market cap of $6.94 billion, a PE ratio of -12.40 and a beta of 0.63.

Hedge Funds Weigh In On Ascendis Pharma A/S

Institutional investors have recently bought and sold shares of the stock. GAMMA Investing LLC bought a new stake in shares of Ascendis Pharma A/S during the 4th quarter worth $25,000. Private Ocean LLC acquired a new position in Ascendis Pharma A/S during the 1st quarter worth $36,000. Quadrant Capital Group LLC boosted its holdings in Ascendis Pharma A/S by 90.4% during the fourth quarter. Quadrant Capital Group LLC now owns 318 shares of the biotechnology company’s stock valued at $40,000 after acquiring an additional 151 shares during the period. EverSource Wealth Advisors LLC grew its position in shares of Ascendis Pharma A/S by 37.6% in the fourth quarter. EverSource Wealth Advisors LLC now owns 333 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 91 shares during the last quarter. Finally, Bessemer Group Inc. increased its stake in shares of Ascendis Pharma A/S by 61.0% in the first quarter. Bessemer Group Inc. now owns 876 shares of the biotechnology company’s stock worth $132,000 after purchasing an additional 332 shares during the period.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.